GROSSI, FRANCESCO
GROSSI, FRANCESCO
DIPARTIMENTO DI MEDICINA E INNOVAZIONE TECNOLOGICA
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)
2018-01-01 de Marinis, Filippo; Ciardiello, Fortunato; Baas, Paul; Crinò, Lucio; Giaccone, Giuseppe; Grossi, Francesco; Hellmann, Matthew D; Mok, Tony S K; Lena, Hervè; Paz-Ares, Luis; Rodriguez-Abreu, Delvys; Von Pavel, Joachim; Gridelli, Cesare
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer
2001-01-01 Sobrero, A; Guglielmi, A; Cirillo, M; Recaldin, E; Frassineti, Gl; Aschele, C; Ravaioli, A; Testore, P; Caroti, C; Gallo, L; Pessi, Ma; Cortesi, E; Turci, D; Grossi, F; Labianca, R
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: When to regret a drug holiday
2021-01-01 Indini, A.; Rijavec, E.; Mandala, M.; Castiglioni, S.; Beltramo, G.; Grossi, F.
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer
2012-01-01 Nuijten, Mjc; Carpeno, Jd; Chouaid, C; Vergnenegre, A; Grossi, F; Bischoff, H; Heigener, D; Walzer, S
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)
2011-01-01 Belvedere, O; Follador, A; Rossetto, C; Merlo, V; Defferrari, C; Sibau, Am; Aita, M; Dal Bello, Mg; Meduri, S; Gaiardo, M; Fasola, G; Grossi, F
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer
2012-01-01 Grossi, F; de Marinis, F; Gebbia, V; Riccardi, F; Caffo, O; Gamucci, T; Ferrau, F; Nardi, M; Moscetti, L; Boni, L; Dondi, D; Galligioni, E
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)
2013-01-01 Groen, Hj; Socinski, Ma; Grossi, F; Juhasz, E; Gridelli, C; Baas, P; Butts, Ca; Chmielowska, E; Usari, T; Selaru, P; Harmon, C; Williams, Ja; Gao, F; Tye, L; Chao, Rc; Blumenschein GR, Jr
A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic
2020-01-01 Zaniboni, A.; Ghidini, M.; Grossi, F.; Indini, A.; Trevisan, F.; Iaculli, A.; Dottorini, L.; Moleri, G.; Russo, A.; Vavassori, I.; Brevi, A.; Rausa, E.; Boni, L.; Dondossola, D.; Valeri, N.; Ghidini, A.; Tomasello, G.; Petrelli, F.
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?
2006-01-01 Tiseo, M; Franciosi, V; Grossi, F; Ardizzoni, A
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial
2021-01-01 Indini, A.; Grossi, F.
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study
2022-01-01 Jin, Kai-Qi; Liu, Xiao-Gang; Guo, Yan-Hua; Wu, Chun-Xiao; Dai, Jie; Li, Jia-Qi; Minervini, Fabrizio; Antonoff, Mara B; Friedlaender, Alex; Addeo, Alfredo; Kocher, Gregor J; Grossi, Francesco; Zhu, Yu-Ming; Zhang, Peng; Jiang, Ge-Ning
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study
2014-01-01 Gridelli, C; de Marinis, F; Ardizzoni, A; Novello, S; Fontanini, G; Cappuzzo, F; Grossi, F; Santo, A; Cortinovis, D; Favaretto, A; Lorusso, V; Galetta, D; Siena, S; Bettini, A; Iurlaro, M; Caprioli, A; LIFE study, Team
Advances in treatment of mesothelioma
2016-01-01 Maggioni, C; Barletta, G; Rijavec, E; Biello, F; Gualco, E; Grossi, F
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
2016-01-01 Schuler, M; Yang, Jc; Park, K; Kim, Jh; Bennouna, J; Chen, Ym; Chouaid, C; De Marinis, F; Feng, Jf; Grossi, F; Kim, Dw; Liu, X; Lu, S; Strausz, J; Vinnyk, Y; Wiewrodt, R; Zhou, C; Wang, B; Chand, Vk; Planchard, D; LUX-Lung, 5 Investigators
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer
2018-01-01 Tagliamento, M.; Genova, C.; Rijavec, E.; Rossi, G.; Biello, F.; Dal Bello, M. G.; Alama, A.; Coco, S.; Boccardo, S.; Grossi, F.
Afatinib for the treatment of advanced non-small-cell lung cancer
2014-01-01 Genova, C; Rijavec, E; Barletta, G; Burrafato, G; Biello, F; Dal Bello, Mg; Coco, S; Truini, A; Alama, A; Boccardo, F; Grossi, F
Afatinib for the treatment of non-small cell lung cancer
2015-01-01 Biello, F.; Maggioni, C.; Rijavec, E.; Genova, C.; Barletta, G.; Gualco, E.; Truini, A.; Coco, S.; Dal Bello, M. G.; Vanni, I.; Alama, A.; Boccardo, F.; Grossi, F.
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition
2015-01-01 Coco, S; Truini, Anna; Alama, A; Dal Bello, Mg; Venè, R; Garuti, Anna; Carminati, ENRICO GIANNI; Rijavec, E; Genova, Carlo; Barletta, G; Sini, C; Ballestrero, Alberto; Boccardo, Francesco; Grossi, Francesco
Alternating bolus and continuous infusion 5-fluorouracil: A strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients
1996-01-01 Guglielmi, A; Aschele, C; Grossi, F; Tixi, L; Sobrero, A
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy
2009-01-01 Tiseo, M; Gridelli, C; Cascinu, S; Crino, L; Piantedosi, Fv; Grossi, F; Brandes, Aa; Labianca, R; Siena, S; Amoroso, D; Belvedere, O; Valentino, B; Bearz, A; Venturino, P; Ardizzoni, A
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT) | 1-gen-2018 | de Marinis, Filippo; Ciardiello, Fortunato; Baas, Paul; Crinò, Lucio; Giaccone, Giuseppe; Grossi, Francesco; Hellmann, Matthew D; Mok, Tony S K; Lena, Hervè; Paz-Ares, Luis; Rodriguez-Abreu, Delvys; Von Pavel, Joachim; Gridelli, Cesare | |
| 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer | 1-gen-2001 | Sobrero, A; Guglielmi, A; Cirillo, M; Recaldin, E; Frassineti, Gl; Aschele, C; Ravaioli, A; Testore, P; Caroti, C; Gallo, L; Pessi, Ma; Cortesi, E; Turci, D; Grossi, F; Labianca, R | |
| A case of sudden brain metastases progression after temporary targeted therapy discontinuation: When to regret a drug holiday | 1-gen-2021 | Indini, A.; Rijavec, E.; Mandala, M.; Castiglioni, S.; Beltramo, G.; Grossi, F. | |
| A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer | 1-gen-2012 | Nuijten, Mjc; Carpeno, Jd; Chouaid, C; Vergnenegre, A; Grossi, F; Bischoff, H; Heigener, D; Walzer, S | |
| A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019) | 1-gen-2011 | Belvedere, O; Follador, A; Rossetto, C; Merlo, V; Defferrari, C; Sibau, Am; Aita, M; Dal Bello, Mg; Meduri, S; Gaiardo, M; Fasola, G; Grossi, F | |
| A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer | 1-gen-2012 | Grossi, F; de Marinis, F; Gebbia, V; Riccardi, F; Caffo, O; Gamucci, T; Ferrau, F; Nardi, M; Moscetti, L; Boni, L; Dondi, D; Galligioni, E | |
| A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) | 1-gen-2013 | Groen, Hj; Socinski, Ma; Grossi, F; Juhasz, E; Gridelli, C; Baas, P; Butts, Ca; Chmielowska, E; Usari, T; Selaru, P; Harmon, C; Williams, Ja; Gao, F; Tye, L; Chao, Rc; Blumenschein GR, Jr | |
| A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic | 1-gen-2020 | Zaniboni, A.; Ghidini, M.; Grossi, F.; Indini, A.; Trevisan, F.; Iaculli, A.; Dottorini, L.; Moleri, G.; Russo, A.; Vavassori, I.; Brevi, A.; Rausa, E.; Boni, L.; Dondossola, D.; Valeri, N.; Ghidini, A.; Tomasello, G.; Petrelli, F. | |
| Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice? | 1-gen-2006 | Tiseo, M; Franciosi, V; Grossi, F; Ardizzoni, A | |
| Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial | 1-gen-2021 | Indini, A.; Grossi, F. | |
| Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study | 1-gen-2022 | Jin, Kai-Qi; Liu, Xiao-Gang; Guo, Yan-Hua; Wu, Chun-Xiao; Dai, Jie; Li, Jia-Qi; Minervini, Fabrizio; Antonoff, Mara B; Friedlaender, Alex; Addeo, Alfredo; Kocher, Gregor J; Grossi, Francesco; Zhu, Yu-Ming; Zhang, Peng; Jiang, Ge-Ning | |
| Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study | 1-gen-2014 | Gridelli, C; de Marinis, F; Ardizzoni, A; Novello, S; Fontanini, G; Cappuzzo, F; Grossi, F; Santo, A; Cortinovis, D; Favaretto, A; Lorusso, V; Galetta, D; Siena, S; Bettini, A; Iurlaro, M; Caprioli, A; LIFE study, Team | |
| Advances in treatment of mesothelioma | 1-gen-2016 | Maggioni, C; Barletta, G; Rijavec, E; Biello, F; Gualco, E; Grossi, F | |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial | 1-gen-2016 | Schuler, M; Yang, Jc; Park, K; Kim, Jh; Bennouna, J; Chen, Ym; Chouaid, C; De Marinis, F; Feng, Jf; Grossi, F; Kim, Dw; Liu, X; Lu, S; Strausz, J; Vinnyk, Y; Wiewrodt, R; Zhou, C; Wang, B; Chand, Vk; Planchard, D; LUX-Lung, 5 Investigators | |
| Afatinib and Erlotinib in the treatment of squamous-cell lung cancer | 1-gen-2018 | Tagliamento, M.; Genova, C.; Rijavec, E.; Rossi, G.; Biello, F.; Dal Bello, M. G.; Alama, A.; Coco, S.; Boccardo, S.; Grossi, F. | |
| Afatinib for the treatment of advanced non-small-cell lung cancer | 1-gen-2014 | Genova, C; Rijavec, E; Barletta, G; Burrafato, G; Biello, F; Dal Bello, Mg; Coco, S; Truini, A; Alama, A; Boccardo, F; Grossi, F | |
| Afatinib for the treatment of non-small cell lung cancer | 1-gen-2015 | Biello, F.; Maggioni, C.; Rijavec, E.; Genova, C.; Barletta, G.; Gualco, E.; Truini, A.; Coco, S.; Dal Bello, M. G.; Vanni, I.; Alama, A.; Boccardo, F.; Grossi, F. | |
| Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition | 1-gen-2015 | Coco, S; Truini, Anna; Alama, A; Dal Bello, Mg; Venè, R; Garuti, Anna; Carminati, ENRICO GIANNI; Rijavec, E; Genova, Carlo; Barletta, G; Sini, C; Ballestrero, Alberto; Boccardo, Francesco; Grossi, Francesco | |
| Alternating bolus and continuous infusion 5-fluorouracil: A strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients | 1-gen-1996 | Guglielmi, A; Aschele, C; Grossi, F; Tixi, L; Sobrero, A | |
| An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy | 1-gen-2009 | Tiseo, M; Gridelli, C; Cascinu, S; Crino, L; Piantedosi, Fv; Grossi, F; Brandes, Aa; Labianca, R; Siena, S; Amoroso, D; Belvedere, O; Valentino, B; Bearz, A; Venturino, P; Ardizzoni, A |